TP53 and acute myeloid leukemia: Based on these promising results, which are particularly interesting in the context of TP53-mutant AML (a category with very poor prognosis but treated only with specific drugs), there is an ongoing phase 3 ENHANCE-2 trial (magrolimab plus azacitidine vs. the physician’s choice of venetoclax plus azacitidine or 7 + 3 chemotherapy) focusing on untreated TP53-mutant AML (NCT04778397) [66], and trial ENHANCE-3 (NCT05079230) is focusing on patients with newly diagnosed AML who are ineligible for intensive hemotherapy.